

The PASPORT Trial

	NAME	TITLE	SIGNATURE	DATE
Author	Lauren Scott	Medical statisticians		
	Gemma Clayton			
Authoriser	Chris Rogers	Co-head of CTEU		



Table of contents

List o	of abb	reviations		3
1.		Introducti	ion to SAP	5
	1.1	Scope		5
	1.2	Editorial	changes	5
	1.3	SAP doc	ument approval	5
	1.4	Skeleton	tables and figures	5
2.		Study ba	ckground and objectives	6
	2.1	Study ba	ckground	6
	2.2	Study ob	jectives	6
	2.3	Primary of	putcome	6
		2.3.1	Cognitive function	6
		2.3.2	Infectious complications	7
	2.4	Seconda	ry outcomes	7
	2.5	Changes	to the study objectives during the course of the study	8
3.		Study po	pulation	9
	3.1	Flow of p	participants	9
	3.2	Randomi	sation	9
	3.3	Protocol	deviations	9
		3.3.1	Eligibility	9
		3.3.2	Transfusion threshold adherence	9
		3.3.3	Other non-adherence	9
	3.4	Withdraw	/als	10
	3.5	Analysis	population	10
	3.6	Safety po	pulation	10
4.		Derivatio	۰ ns	10
	4.1	Primary of	outcomes: cognitive function	11
	4.2	Seconda	ry outcomes	12
	4.3	Protocol	deviations	18
	4.4	Other var	riables	20
5.		Statistica	I analyses	23
	5.1	Baseline	data	23
	5.2	Primary a	and secondary outcome data	23
		5.2.1	Adjustment in models	23
		5.2.2	Descriptive analyses	23
		5.2.3	Analysis models	23
		5.2.4	Statistical significance	25
		5.2.5	Model assumptions	25
		5.2.6	Subgroup analyses	25
		5.2.7	Sensitivity analyses	25



		5.2.8	Missing data	.26
		5.2.9	Multiple testing	.26
	5.3	Safety da	ta	.26
6.		Bibliograp	hy	.27
7.		Amendme	ents to the SAP	.27
APPE	NDIX	A: Skelet	on tables and figures	.27
APPE	NDIX	B: ASEPS	SIS SCORES	.66

List of abbreviations

Acronym	Details	
AIC	Akaike information criterion	
AKIN	Acute Kidney Injury Network	
ARDS	Acute respiratory distress syndrome	
AVLT	Auditory Verbal Learning Test	
AFT	Accelerated failure time	
BIC	Bayesian information criterion	
CABG	Coronary artery bypass graft	
CI	Confidence interval	
COWAT	Controlled Oral Word Association Test	
СРВ	Cardiopulmonary bypass	
CRF	Case report form	
CVA	Cerebrovascular accident (stroke)	
EQ5D	EuroQol five-dimension scale	
FFP	Fresh Frozen Plasma	
GHQ	General health questionnaire	
GM	Geometric mean	
GMR	Geometric mean ratio	
HAD	Hospital anxiety and depression scale	
HCT	Haematocrit	
HDU	High dependency unit	
HR	Hazard ratio	
ICU	Intensive care unit	
IQR	Inter quartile range	
ITT	Intention to treat	
MAR	Missing at random	
MD	Mean difference	
NIRS	Near Infra-Red Spectrometry	

STATISTICAL ANALYSIS PLAN PASPORT



Acronym	Details	
OR	Odds ratio	
RBC	Red blood cells	
RCT	Randomised controlled trial	
SAP	Statistical analysis plan	
SD	Standard deviation	
SAE	Serious adverse event	
SIRS	Systemic inflammatory response syndrome	
STEMI	ST-elevation myocardial infarction	
TIA	Transient Ischaemic Attack	
TITRE2	A multi-centre randomised controlled trial of <u>T</u> ransfusion <u>Indication</u> <u>T</u> hreshold <u>Re</u> duction on transfusion rates, morbidity and healthcare resource use following cardiac surgery	
WAIS-R	Wechsler Adult Intelligence Scale- Revised	



1. INTRODUCTION TO SAP

1.1 Scope

The PASPORT trial aims to recruit 200 patients. This statistical analysis plan (SAP) details information regarding the statistical analysis of the completed PASPORT trial and covers all analyses of trial data outlined in the study protocol, with the exception of the health economic analyses.

1.2 Editorial changes

Any changes made to this SAP after approval must be clearly justified and documented as an amendment at the end of this document. The SAP should then be re-approved.

1.3 SAP document approval

The trial statistician should authorise this document.

1.4 Skeleton tables and figures

Throughout this document references are made to any skeleton tables and figures to be used in the reporting of the study (e.g. **Figure F1** or **Table T1**). Such tables and figures can be found in **Appendix A** of this document, and are intended as a guide for trial reporting. Final versions of the tables/figures may differ: tables may be combined, and/or their layout or numbering may differ. However the content should be consistent with **Appendix A**.



2. STUDY BACKGROUND AND OBJECTIVES

2.1 Study background

The PASPORT trial is a multi-centre blinded randomised controlled trial (RCT) to compare generic and patient-specific algorithms for optimising tissue oxygenation during CPB in adult cardiac surgery patients. Centres include Bristol, Leicester and Hull.

Compared to the generic algorithm (including a haematocrit transfusion threshold of 23), we hypothesise that the patient-specific, goal-directed algorithm (based on optimising regional cerebral oxygen saturation), combined with a pre-specified "restrictive" haematocrit transfusion threshold of 18, will result in fewer RBC transfusions and will reduce complications arising from unnecessary transfusion and from low oxygen levels during CPB.

2.2 Study objectives

- A. To compare the effects of the patient-specific, goal-directed, algorithm versus the generic algorithm in terms of cognitive function and post-operative infectious complications.
- B. To compare the effects of the patient-specific, goal-directed algorithm versus the generic algorithm with respect to a range of secondary outcomes.
- C. To estimate the cost-effectiveness of the patient-specific, goal-directed algorithm versus the generic algorithm and describe this in terms of cost-effectiveness acceptability curve.

Note objective C is not covered in this SAP.

2.3 Primary outcome

The patient-specific algorithm is designed both to maintain cerebral oxygen delivery better, and to reduce the likelihood of a patient having an unnecessary RBC transfusion, compared to the generic algorithm. Therefore, there are 'co-primary' outcomes designed to measure both hypothesised benefits of the patient-specific algorithm.

We will measure **cognitive function** three months after surgery, and **infectious complications** during the first three months after surgery. These will be measured to determine whether the patient-specific algorithm (designed to optimise cerebral oxygenation and restrict transfusion) will improve cognitive outcomes, and reduce infectious complications (a potential risk of unnecessary transfusion), compared to current practice (where cerebral oxygenation monitoring is not implemented and a generic transfusion threshold is used).

2.3.1 Cognitive function

Cognitive function will be assessed by a qualified examiner blinded to treatment allocation preoperatively, on or between four and seven days post-operatively and again at three months. Recommended cognitive domains will be tested as follows (tests will be performed in a fixed order):

- Attention: First trial of the AVLT, Sustained and divided attention: Trail- Making Test parts A and B [1,3]
- Verbal memory: Rey Auditory Verbal Learning Test (AVLT) [1,2]
- Visuo-spatial: Block Design from the Wechsler Adult Intelligence Scale- Revised (WAIS-R) test [4]
- **Psychomotor speed:** Digit Symbol Test from the Wechsler Adult Intelligence Scale– Revised (WAIS-R) test [4]
- Executive function/Verbal fluency: Controlled Oral Word Association Test (COWAT) [5].
- Motor coordination: Grooved Pegboard Test, dominant and non-dominant hand [1]



To help interpret the cognitive function data, the following assessments related to the cognitive testing will be carried out for all participants:

- The Wechsler Test of Adult Reading will provide a measure of intellectual ability [6], preoperatively only.
- Documentation of medications known to interfere with neuropsychological functions (including hypnotics, sedatives, neuroleptics, anxiolytics, antidepressants, and β-blockers) preoperatively, 4-7 days post-operatively and three months post-operatively.
- Assessment of patient's current mental health using the General Health Questionnaire (GHQ-30) and Hospital Anxiety and Depression Scale (HAD) [7] preoperatively, 4-7 days post-operatively and three months post-operatively, to take into account the potential interaction between post-operative cognition and mood.

2.3.2 Infectious complications

Serious infectious events will be defined by:

Infectious events	Definition / method of verification		
Sepsis	Defined by the following two conditions, both of which must be satisfied for sepsis to be documented:		
	(a) Antibiotic treatment for suspected infection, and		
	(b) The presence of SIRS ¹ within 24 hours prior to start of antibiotic treatment		
Wound infection	ASEPSIS score >20; sternum, leg and arm (if applicable). Wounds will be assessed at least once during a participant's hospital stay and details of the ASEPSIS assessment added to the study CRF. A questionnaire will be administered at 3 months to identify wound infections arising after discharge.		

Sepsis occurring post-discharge will only contribute to the primary outcome if the event results in admission to hospital or death. A cumulative infection score will be calculated by supplementing data on wound infections (the ASEPSIS score that describes signs and symptoms of wound infection on a continuous scale), with data describing the severity of sepsis. We are developing this score with data from our RCT of a "restrictive" versus "standard" generic post-operative transfusion threshold (TITRe2) (see section 2.5).

2.4 Secondary outcomes

Data will also be collected to characterise the following secondary outcomes at three months (unless otherwise stated):

1) Units of RBC and other blood components transfused: the number of units of RBC and other blood components transfused during the operative period and post-operative hospital stay will be recorded

2) Cerebral oxygenation during the operative period: NIRS readings will be recorded for both groups for comparison. Monitoring will start before pre-oxygenation and anaesthetic induction and continue until the patient leaves theatre.

3) Oxygen delivery and utilisation during CPB: serial measurements of oxygen delivery (arterial) and utilisation will be collected from the clinical perfusion record.

¹ SIRS - systemic inflammatory response syndrome. SIRS is central to the diagnosis of infective complications. It will be defined as ≥ 2 of the following conditions: temperature >38°C or <36°C; heart rate >90 beats/minute; respiratory rate >20 breaths/min or PaCO₂ <32 mm Hg or PaCO₂ <4.3 kPa; WBC count >12,000/mm³ or <4,000/mm³. Blood test results and temperature will be classified using standard reference ranges.



4) EuroQol EQ5D: will be assessed at baseline and at six weeks and three months after surgery.

5) Length of ICU / HDU stay

- 6) Length of hospital stay
- 7) Clinical outcomes, defined as:

(a) Stroke (validated by CT scanning); blinded assessment of brain imaging (CT or MRI), in association with new onset focal or generalised neurological deficit (defined as deficit in motor, sensory or co-ordination functions);

- (b) ST elevation myocardial infarction accompanied by troponin > 5 ng / ml;
- (c) Post-operative acute kidney injury (defined as AKIN criteria stage 1, 2 or 3);

(d) Respiratory complications i.e. re-intubation, ventilation > 48 hours, tracheostomy, or acute respiratory distress syndrome (ARDS).

8) Cumulative resource use, cost and cost-effectiveness (not included in this SAP)

9) All-cause mortality within 30 days of surgery

10) Biochemical markers of organ injury:

The following will be measured from venous blood samples taken preoperatively, on return to ITU, and 6 hours, 24, 48 and 96 hours post-operatively. The use of these markers has been described previously:

- (a) S100 / 100B (brain);
- (b) Troponin I or T (heart);
- (c) Creatinine clearance (derived from serum creatinine) (kidney);
- (d) Interleukins (systemic inflammation).

The following will be measured from urine collected for over a 3 hour period (one sample taken preoperatively, and three samples taken over the first two post-operative days);

(e) Urinary creatinine and electrolytes, and urinary microalbumin, NGAL, IL18, LFABP, KIM-1 [8,9], alpha- and pi- glutathione-S-transferase (markers of tubular and glomerular renal injury)

11) Compliance with transfusion protocol:

Data will be collected for all patients during surgery to characterise compliance with the randomly assigned transfusion protocols. Haematocrit is measured at regular intervals during surgery and in cardiac ICU and all of these data will be collected. When a transfusion decision is made which is inconsistent with the allocated protocol, the attending doctor will be required to explain the decision and this will be documented on the CRF.

2.5 Changes to the study objectives during the course of the study

It states in the protocol that as part of the primary outcome, an infection score will be derived based on work in the TITRe2 trial. The results from the TITRe2 trial (n=2007) suggest that infection rates will be similar in the two groups and that serious infections will be few [10]. In light of these findings an infection score has not been developed. Additionally, the infection rates are expected to be low, (approx. 20% sepsis and 5% asepsis in TITRe2 trial). Therefore a binary infection indicator will be derived to include patients who experience sepsis and/or asepsis. The number of infections and number of sites infected will also be described as a secondary outcome; the primary outcome will be based on neuro-cognitive outcomes only.

Alpha and pi- glutathione-S-transferase (markers of tubular and glomerular renal injury) have been excluded from the analysis as the ELISA for each of these respectively did not work and the results should be considered meaningless. This was fed back to the manufacturer.



3. STUDY POPULATION

The study population consists of all patients aged 16 years and over undergoing valve or combined CABG and valve surgery at the Bristol Royal Infirmary, Glenfield Hospital or Castle Hill Hospital. For specific exclusion criteria see section 5.2.

The trial originally planned to recruit 150 patients. This was increased to 200 patients due to lower correlations between repeated measures of cognitive outcomes than expected, and higher loss to follow up than expected for the three month cognitive assessments in the early stages of the trial.

3.1 Flow of participants

The duration of follow-up in the trial is three months after surgery. After discharge from hospital, follow-up data will be collected as follows:

- Cognitive function and related assessments, and infectious complications will be assessed at a follow-up visit at three months.
- EuroQol EQ5D will be assessed at six weeks (via postal questionnaire) and at three months (at the follow-up visit).

If the distribution of timings is similar for both groups then all data will be included. If the distribution differs significantly (p<0.05), then pre-defined windows will be used. The windows will be chosen to make maximal use of the data, excluding extreme outliers. Any observations excluded will be described. Participant flow will be described via a flowchart (**Figure F1**).

3.2 Randomisation

Patients are randomly assigned to the two treatment groups in a 1:1 ratio using stratification to achieve balance across centres and type of surgery (valve or CABG and valve). Random allocations are generated by computer once the relevant baseline data (information to identify the patient and the type of surgery) have been entered into the system).

3.3 **Protocol deviations**

The following types of protocol deviation will be considered:

3.3.1 Eligibility

- Patient did not meet the study eligibility criteria but was treated in the study.
- Patient did not receive trial intervention.

3.3.2 Transfusion threshold adherence

- Patient in the conventional group received transfusion(s) when HCT is above 23.
- Patient in the conventional group did not receive a transfusion when HCT dropped below 23.
- Patient in the patient-specific group received transfusion(s) when HCT is above 18 and other parts of the Murkin protocol have not been attempted first.
- Patient did not receive a transfusion when HCT dropped below 18 (this applies to both groups).

3.3.3 Other non-adherence

- The Murkin protocol was not followed for patients in the patient-specific group when NIRS reading dropped below 70% of baseline or an absolute value of 50%.
- The Murkin algorithm was followed for a patient in the conventional group (i.e. patient crossedover between treatment groups)



Note it may be possible for patients to be classified as a protocol deviation for more than one reason.

The frequency of each type of deviation will be tabulated by treatment allocation (**Table T1**) with full details given in separate listings (**Table T2**)

3.4 Withdrawals

Patients (or clinicians on their behalf) can withdraw from the study at any time post-randomisation (including prior to their surgery). In some cases patients may be happy for data collection to continue, and therefore such patients will be included in the study analyses on an intention to treat (ITT) basis, see **section 3.5**.

Data on all withdrawals is captured on a specific case report form (CRF), and will be tabulated by treatment allocation (**Table T3**).

3.5 Analysis population

The analysis population consists of all randomised patients excluding:

- Patients who died or withdrew after randomisation but prior to surgery, because surgery did not take place.
- Patient withdrawals at any time who were unwilling for data collected to be used

The main trial analyses will be performed on an intention to treat (ITT) basis.

3.6 Safety population

The safety population consists of the same patients as the analysis population with the addition of any patients who died after randomisation but prior to surgery. Safety data will be presented on an ITT basis for consistency, as the study outcomes include safety outcomes (e.g. sepsis/asepsis). Safety outcomes by treatment received (where different from treatment allocated) will be included as footnotes.



4. DERIVATIONS

4.1 **Primary outcomes: cognitive function**

The primary outcome is neurocognitive data in which six dimensions will be assessed and a summary score for each derived: Attention, verbal memory, psychomotor speed, verbal fluency and visual motor coordination.

COGNITIVE FUNCTION

(assessed pre-operatively, and 5 days and 3 months post-op) Scaled/standard scores will be used throughout

1. Attention - TRAIL MAKING

The patient draws lines to connect both the numbers and letters in ascending order to form a trail and this is then timed in seconds.

Task B score will be reported – no derivation required.Interpretation:The lower the score (in seconds), the better a patient's attention.

2. Verbal memory - RAVLT

Trial 6 is the recall trial in which patients must recall as many words as they can from the first 5 learning trials after having an interference trial.

Standard scores (adjusted for age) will be reported. No derivation required – recorded directly on CRF.

Interpretation: The higher the score, the better a patient's verbal memory.

3. Visuo-spatial skills - WAIS III (Wechsler)

Block design The patient has to copy designs shown on paper using a set of blocks.

Scaled scores (adjusted for age) will be reported. No derivation required.

Interpretation: The higher the score, the better a patient's visuo-spatial skills. Low scores are indicative of brain insult and those with dementia.

4. Psychomotor speed - WAIS III (Wechsler)

Digital symbol
codingPatients had to copy symbols on a piece of paper and had a maximum of 2
minutes.

Scaled scores (adjusted for age) will be reported. No derivation required.

Interpretation: The higher the score, the better a patient's psychomotor speed. Low scores are indicative of brain insult and those with dementia.

5. Verbal fluency - MULTILINGUAL APHASIA (COWAT)

Patients come up with a list of as many words they can think of in a max of 1 minute, not including names/proper nouns.

An overall score, adjusted for years of education and age, will be derived. The appropriate number from the table below will be added to the raw score.

Interpretation: The higher the score, the better a patient's verbal fluency.

6. Visual motor coordination - PEG BOARD

The time it takes to fill up a peg board from left to right. This is done using both a patient's dominant and non-dominant hand.

The dominant hand will be used – no derivation required.

Interpretation: The lower the score (in seconds), the better a patient's visual motor coordination.



Multilingual aphasia (COWAT) adjustment

	Age			
Years in education	25-54	55-59	60-69	
<9	8	10	12	
9-11	5	7	9	
12-15	3	4	6	
16+	0	1	3	

4.2 Secondary outcomes

The secondary outcome variables will be derived as follows:

	New variable	Rules		
1	Units of RBC and other blo	s of RBC and other blood components transfused: the number of units		
	of RBC and other blood co	of RBC and other blood components transfused during the operative		
	period and post-operative hospital stay will be recorded.			
	RBC units transfused intra-	= Total number of intra-op RBC units listed on		
	ор	CRF C6 if any intra-op transfusions of RBC=yes		
		=0 if any intra-op transfusions of RBC=no		
		Else missing		
	RBC units transfused post-	= Total number of post-op RBC units listed on		
	op .	CRF D10 if 'any post-op transfusions of RBC'=yes		
	•	=0 if 'any post-op transfusions of RBC'=no		
		Else missing		
	Any FFP	YES if intra-op FFP≥1 OR post-op FFP≥1		
	,,	NO if intra-op FFP=0 AND post-op FFP=0		
		Else missing		
	Any platelets	YES if intra-op platelets≥1 OR post-op platelets		
	, ity platelete	≥1		
		NO if intra-op platelets =0 AND post-op platelets		
		=0		
		Else missing		
	Any cryoprecipitates	YES if intra-op cryoprecipitates≥1 OR post-op		
		cryoprecipitates ≥1		
		NO if intra-op cryoprecipitates =0 AND post-op		
		cryoprecipitates =0		
		Else missing		
	Any activated factor VII	YES if intra-op activated factor VII = yes OR post-		
		op activated factor VII =yes		
		NO if intra-op activated factor VII =no AND post-		
		op activated factor VII =no		
		Else missing		
2	Cerebral oxygenation duri	ng the operative period: NIRS readings will be		
recorded for both groups for comparison. Monitoring v		or comparison. Monitoring will start before pre-		
	tic induction and continue until the patient			
	leaves theatre.	-		
	Cerebral oxygenation	Operative period:		
	during the operative period	Time of operation end – start NIRS was applied.		
	(NIRS)	Cerebral oxygen:		



	New variable	Rules
		Area under the curve (of the average of the left
		and right oximetry measures) will be used to
		summarise multiple measurements per patient.
		The minimum cerebral oxygen during the
		operative period will be descriptively summarised.
3	Oxygen delivery and utilis oxygen delivery and utilis record.	sation during CPB: serial measurements of sation will be collected from the clinical perfusion
	Oxygen deliver n during CPB	CPB :(End of CPB – start of CPB). Serial measurements of arterial oxygen saturation (CRF C3) measured at five fixed time points (Start of CPB, 20 minutes after start of CPB, 40 minutes after start of CPB, pre-warm and pre-wean). Oxygen delivery:
		$= CO^*CaO_2 * 10$ = CO^*[(Hb^*1.39^*SaO_2)+(PaO_2^*0.003)] * 10 = CO^*[(Hb^*1.39^*SaO_2)+(PaO_2^*0.003)] * 10 = CO^*[((Hct^*0.333)^*1.39^*SaO_2)+(PaO_2^*0.003)]^*10 = ml O_2/min where CO=Cardiac output – pump flow – l/min where SaO_2=arterial oxygen saturation - % where Hb=Hct^*0.333
	Oxygen utilisation during CPB	= $CO^*(CaO_2 - CVO_2)^*10$ = $CO^*(Arterial - venous O_2 difference)^*10$ = ml O ₂ /min where CVO2= Hb*1.39*SVO2
		where Hb=Hct*0.333
1	EuroQol EQ5D: will be as	sessed at baseline and at six weeks and three
-	months after surgery.	
	EQ5D single summary index score	Five digit 'state' score is derived as: 10000*mobility score + 1000*self-care score + 100*usual activities score + 10*pain/discomfort score + anxiety/depression score. Each state score is then assigned a single summary index score according to reference scales. These index scores are numerical and range from -0.59 to 1.00, with a score of 1.00 denoting perfect health.
	EQ5Dstate score	= 10000*mobility score + 1000*self-care score + 100*usual activities score + 10*pain/discomfort score + anxiety/depression score.
	EQ5D single summary utility score	Each five digit state score will be assigned a single summary utility score according to standard scales (this can also be calculated using the eq5d command in Stata).
		These utility scores are numerical and range from -0.59 to 1.00, with a score of 1.00 denoting perfect health. If any of the five components of the state score is missing, the overall score will be missing.



	New variable	Э	Rules		
5	Length of IC	CU / HDU stay	-		
	CICU/ HDU (hours)	length of stay	Duration of initi (CICU/HDU) st Earliest of (war date) –(CICU/H	ial cardiac intensive care unit ay: d admission date/time, discharge IDU admission date/time) * 24	
	CICU/HDU I censoring va died in CICI	ength of stay ariable (patient	If readmitted to readmissions as the above time (Date/time of n readmission) – readmission) * Note. As discha associated, mid discharges and patient died. YES if patient of NO otherwise	CIC/HDU= yes then the should be calculated and added to as follows: ext admission following relevant (Date/time of CICU/HDU 24 arge does not have a time dday will be assumed for 5 SAE onset time will be used if died during ICU/HDU stay	
	Unation of v (hours)	ward stay	Calculated as the sum of the following components: Duration of initial ward stay: Earliest of (Date/time of next admission fol ward admission, discharge date) – (Ward admission date/time) * 24 Duration of any readmissions to ward: (Date/time of next admission following war readmission) –Date/time of ward readmiss 24		
			NO otherwise		
6	Length of h	ospital stay			
	Total length Total length censoring va died in hosp	of stay (days) of stay ariable (patient ital)	Date of discharge – operation date YES if patient died during hospital stay NO otherwise		
	In hospital d	eath indicator	YES if discharg NO otherwise	e destination= patient died	
7	Clinical out	comes, defined	as		
<u>(a)</u>	Sepsis	In-hospital YES, if patien one antibiotic hospital with S NO, if: - Patient wa antibiotics operative s prophylaxis - For all cou antibiotics: > SIRS to missing MISSING oth	t had at least course in $SIRS total^{1} \ge 2$ s not given any in their post- stay (excluding s), OR rses of tal=0 and $SIRSt^{1} \le 1otal=1 and SIRSt=0perwise$	YES, if a readmission has been recorded on the three month follow up questionnaire and date of admission is within 3 calendar months of operation date and (either antibiotics for infection=yes or an infection has been reported at follow up) NO, if the above conditions are not met and patient completed 3 month follow-up questionnaire/ died MISSING, otherwise	



	New variable	Rules	
	New variable Asepsis ² Any infection	Rules YES, If at least one wound with in-hospital asepsis score >20 NO, if all scored wounds have in-hospital asepsis score ≤ 20, and no wounds have missing in-hospital asepsis scores MISSING, otherwise YES: If sepsis in-hospital=yes up=yes OR asepsis in-hospital=follow up =yes; NO: If sepsis in-hospital=no Al AND asepsis in-hospital =no A =no; MISSING, otherwise	YES, if at least one wound with post-discharge asepsis score >20 NO, if all scored wounds have post-discharge asepsis score ≤ 20, and no wounds have missing post-discharge asepsis scores MISSING, otherwise OR sepsis at 3 month follow =yes OR asepsis at 3 month ND sepsis at 3 month follow up=no ND asepsis at 3 month follow up
(b)	Stroke (valida MRI), in assoc (defined as de	ted by CT scanning); blinded as ciation with new onset focal or ge	sessment of brain imaging (CT or eneralised neurological deficit
	Stroke	 YES, if on CRF Stroke=Yes Date/time o randomisati Verified by verification NO, if: Stroke=No, Stroke=No, Stroke=Yes of randomis Stroke=Yes verified by N MISSING, othe **AFTER DISC YES, if a readm completed with 	D8: a, AND f stroke≥date/time of ion, AND CT=Yes or verified by MRI=Yes, or criteria missing OR and date/time of stroke <date time<br="">sation, OR and verified by CT=No and MRI=No rwise HARGE: hission form (X1) has been :</date>
		 Stroke=Yes Date of admosperation, A Verified by a verification NO, if the above patient completed MISSING, othe 	a, AND nission is within 3 months of AND CT=Yes or verified by MRI=Yes, or criteria missing e conditions are not met and ted 3 month follow-up/died rwise
(C)	ST elevation r	nyocardial infarction accompanie	ed by troponin > 300 ng / L
	STEMI	YES if - ST elevation - (troponin T missing and either new 0 contiguous - Date/time o randomisati NO if ST elevat	n myocardial infarction = Yes AND > 300 ng / I) OR troponin T d an ECG has been performed with Q's or new ST depression in 2 leads) AND f STEMI ≥date/time of on tion myocardial infarction = No OR



	New variable	Rules			
(d)	Post-operative acute kidney	 Date/time of STEMI <date li="" of="" or<="" randomisation="" time=""> (ST elevation myocardial infarction = Yes AND troponin T ≤ 300 ng /l) OR troponin T is missing and an ECG has not been performed OR an ECG has been performed and there are no new Q's or new ST depression in 2 contiguous leads For Leicester Troponin I is measured and the limit defined as >400 ng/l Missing otherwise injury (defined as AKIN criteria stage 1, 2 or 3 </date>			
	AKI	 YES, if on CRF D7: AKI=Yes, AND Date/time of AKI ≥date/time of randomisation, AND Acute Kidney Injury Network (AKIN) criteria stage 1, 2 or 3=Yes or missing NO, if: AKI=No, OR AKI=Yes and date/time of AKI<date of<br="" time="">randomisation, OR</date> AKI=Yes and AKIN criteria stage 1, 2 or 3=No MISSING, otherwise 			
		 **AFTER DISCHARGE: YES, if a readmission form (X1) has been completed with: AKI=Yes, AND Date of admission is within 3 months of operation, AND AKIN criteria stage 1, 2 or 3=Yes or missing NO, if the above conditions are not met and patient completed 3 month follow-up/died MISSING, otherwise 			
(e)	Respiratory complications i. or acute respiratory distress Respiratory complications	 e. re-intubation, ventilation > 48 hours, tracheostomy, syndrome (ARDS) Total ventilation time (hours): 			
		([extubation date + extubation time] – [operation end date + operation end time])*24 + ([first re- extubation date + first re-extubation time] – [first re-intubation date + first re-intubation time])*24 + any additional periods of ventilation			
		Respiratory complications: YES if re-intubation=yes OR ventilation>48 hours OR tracheostomy=yes OR ARDS=yes NO if re-intubation=no AND ventilation≤48 hours AND tracheostomy=no AND ARDS=no Otherwise missing			
8	Cumulative resource use, SAP)	cost and cost-effectiveness (not covered in this			
0	All-cause mortality within 30 days of surgery				



	New variable	Rules	
	Death within 30 days of	YES if patient had an SAE AND reason for	
	surgery	SAE=resulted in death AND (death date-operation date)≤30 days	
		NO if patient didn't have an SAE OR (patient did	
		have SAE(s) but reason for SAE(s) is not resulted	
		in death) OR (patient had an SAE and reason for	
		SAE=resulted in death but (death date-operation	
		date)>30 days)	
10	Biochemical markers of organ injury		
(c)	Creatinine clearance (derived from serum creatinine) (kidney)	=[(urinary creatinine (mg/dl))/(serum creatinine (mg/dl)]*[(volume of urine (ml)/(collection period (min)]	
		N.B Converison of units is required: 1 mg/dl = μmols/l / 88.4 1 mg/dl=mmol/l * 18.018	

Notes:

¹ For stroke, STEMI, AKI and ARDS the event will default to NO if the documentary evidence does not support that the event occurred.



4.3 **Protocol deviations**

The following protocol deviations require derivations to be made:

New variable	Rules			
Murkin protocol is defined as	YES if any of the following are acted upon (CRF C5):			
having been actioned if any of the following criteria are met	 CPP<60mmHg and metaraminol was administered 			
	 No effect and CPP<80 mmHg and metaraminol was administered 			
	 PaCO₂<35 mmHg and gas flow reduced 			
	 FiO₂<0.6 and FiO₂ was raised 			
	– No effect and FiO ₂ <1.0 and FiO ₂ was raised to 1.0			
	 Decrease in cerebral metabolic rate and increase of propofol or increase in pump flow to maximum tolerated by oxygenator 			
	 Target is not met and Hct 18-23 and 1 unit of RBC was transfused 			
	NO otherwise			
Eligibility				
Ineligible but treated	YES if eligibility criteria not met and patient treated in the trial NO otherwise			
Did not receive any trial intervention	YES if eligibility criteria met and patient treated in the trial but did receive any trial intervention NO otherwise			
Transfusion threshold adherence				
Transfused above HCT 23 in conventional group	YES (if an RBC transfusion is given in the period when HCT>23) and (patient is in the conventional group) NO otherwise			
Did not receive a transfusion when HCT dropped below 23 (conventional group)	YES if (an RBC transfusion has not been given in a period after HCT<23) and (patient is in the conventional group) NO otherwise			
Transfused above HCT 18 in patient-specific group without Murkin protocol being followed	YES if (an RBC transfusion has been given in the period when HCT>18) and (the Murkin protocol has not been followed) and (patient is in the patient-specific group) NO otherwise			
Did not receive a transfusion when HCT dropped below 18 (patient- specific and conventional group)	YES if (an RBC transfusion has not been given in the period after HCT<18) NO otherwise			
Other non-adherence				
Murkin protocol not followed when NIRS reading drops below 70% of baseline or absolute value of 50%	 YES if none of the Murkin protocol has been actioned and NIRS reading drops below 70% of baseline or absolute value of 50% and patient is in the patient-specific group NO otherwise 			



Murkin algorithm followed for patient in conventional group i.e. patient crossed-over between treatment groups

YES if any of the Murkin protocol has been actioned and patient is in the conventional group **NO** otherwise



4.4 Other variables

Details for any other variables which are derived for use in any other figures or tables are given below:

New variable	Rules
Reason for exclusion from trial	If any eligibility criteria not met; then = Ineligible
	If all eligibility criteria met but patient not approached; then = Not approached
	If all eligibility criteria met, and patient was approached but did not consent; then = Did not consent
	Otherwise = Other
Age	(Operation date – date of birth)/365.25
BMI	(Weight (kg) / Height (cm)²) * 10,000
Operation length (hours)	(Operation end time - start time)*24
EuroSCORE	For all patients start with Euroscore of zero and add points according to the following rules:
	- Age: <60=0, 60-64=1, 65-69=2, 70-74=3, 75-79=4, 80-84=5, 85-90=6, >90=7
	 Sex: Male=0, Female=1
	 Chronic pulmonary disease: add 1
	 Extracardiac arteriopathy, neurological dysfunction, Creatinine >200 µmol/l, unstable angina, pulmonary hypertension, recent MI, surgery other than isolated CABG: add 2 for each
	 Previous cardiac surgery, active endocarditis, critical
	preoperative state, surgery on thoracic aorta: add 3 for each
	 Postinfarct septal rupture: add 4
	LV function: Good (>50%)=0, Mod (30-50%)=1, Poor (<30%)=3
Cross-clamp time (minutes)	=Operation end time – operation start time
Total ventilation time (hours)	Calculated as the sum of the following components:
	([extubation date +extubation time] – [operation end date +
	operation end time])*24 + ([first re-extubation date + first re-
	extubation time] – [first re-intubation date + first re-intubation
Time between randomisation	time]) + any additional periods of ventilation
and previous MI (months)	(vear of operation – vear of previous MI)*12 + month of operation
(– month of previous MI
MI within last 90 days	If previous MI = yes and time between randomisation and
	previous MI \leq 3 months; then =Yes
Time between randomisation	(withdrawal date – randomisation date)
and withdrawal (days)	
Medications known to interfere	YES: if at least one of the medications listed (Hypnotics,
with neuropsychological	Sedatives, Neuroleptics, Anxiolytics, Antidepressants, β-blockers)
Tunctions	NO: if all of the medications listed are no
	MISSING: otherwise
SAE's	· · · · · · · · · · · · · · · · · · ·
Serious adverse event	Maximum of intensity variable on initial SAE form and all follow-up
SAE relatedness	Maximum (worst case scenario) of relatedness variable on initial
	SAE form and all follow-up SAE forms
SAE resolution date and time	SAE end date and time on final follow-up SAE form (or initial SAE
	form if no follow-up forms required)



New variable	Rules
Timing of SAE	If (SAE onset date + SAE onset time) < (operation date + operation start time): then = Pre-surgery
	If (operation date + operation start time) < (SAE onset date + SAE onset time) and SAE onset date ≤ date of discharge; then = Post-surgery but pre-discharge
Cardiac arrest	If SAE onset date > date of discharge; then = Post-discharge YES: If resuscitation (involving ventricular defibrillation/DC shock) = yes & chest re-opening=yes & external/internal cardiac massage=yes:
	NO: if resuscitation = no; MISSING: otherwise
Haemodynamic support	YES: If [Inotropes = yes OR Intra-aortic Balloon Pump (IABP) = yes OR Pulmonary artery catheter = yes OR Vasodilator = yes OR Low cardiac output = yes];
	NO: if [Inotropes = no AND IABP = no AND Pulmonary artery catheter = no AND Vasodilator = no AND Low cardiac output = no]; MISSING: otherwise
Arrhythmias	YES: If [Supraventricular Tachycardia (SVT)/Atrial Fibrillation (AF) requiring treatment = yes OR Ventricular Fibrillation (VF)/Ventricular Tachycardia (VT) requiring treatment = yes OR New pacing = yes];
	NO: if [SVT/AF requiring treatment = no AND VF/VT requiring treatment = no AND New pacing = no];
Pulmonary complications	YES: If [Re-intubation and ventilation = yes OR Tracheostomy = yes OR Mask Continuous Positive Airway Pressure (CPAP) = yes OR Acute Respiratory Distress Syndrome (ARDS) = yes OR Pneumothorax or effusion requiring drainage = yes];
	NO: if [Re-intubation and ventilation = no AND Tracheostomy = no AND Mask CPAP = no AND ARDS = no AND Pneumothorax or effusion requiring drainage = no]; MISSING: otherwise
Thromboembolic complications	YES: if pulmonary embolus=Yes
	NO: if pulmonary embolus=No
Renal complications	YES: if haemofiltration/dialvsis=Yes
	NO: if haemofiltration/dialysis=No MISSING: otherwise
Gastrointestinal (GI) complications	YES: If [Peptic ulcer/GI bleed/perforation = yes OR Pancreatitis = yes OR Other GI complication = yes];
	NO: if [Peptic ulcer/GI bleed/perforation = no AND Pancreatitis = no AND Other GI complication = no];
	MISSING: Otherwise
Neurological complications	YES: If [Permanent stroke = yes OR Transient Ischaemic Attack (TIA) = yes];
	NO: if [Permanent stroke = no AND TIA = no]; MISSING: Otherwise
Re-operation	YES: If re-operation is due to tamponade, bleeding, mediastinitis, cardiac arrest, low cardiac output or other cause; NO: Otherwise
Excess bleeding	YES: If bleeding is greater than or equal to 400ml/h for I hour or 200ml/h for 4 hours ; NO: Otherwise



New variable	Rules
Wound dehiscence	YES: If Wound dehiscence requiring rewiring or treatment = yes;
	NO: if Wound dehiscence requiring rewiring or treatment = no; MISSING: Otherwise
GHQ30	Sum of Likert scale scores (0-1-2-3) [11] across 30 questions giving a minimum of 0 and maximum of 90. For missing data, the standard procedure is to count omitted items as low scores (0).
	A high score represents a more severe condition. A threshold of 72 will be used to dichotomise the outcome into 'severe'/'non-severe' (≥72 = 'severe', <72 = 'non-severe').
HADS	The questionnaire features seven questions for anxiety and seven for depression. Each item is scored from 0-3. The scores from the seven questions are added to give a separate score for anxiety and depression; the maximum score for each is 21.
	A high score represents more anxiety/depression. A threshold of 8 will be used to dichotomise both scores [12].
	For missing data, the score for a single missing item from a subscale is inferred by using the mean of the remaining six items. If more than one item is missing, then the subscale should be judged as invalid and cannot be used.

¹SIRS elements are defined as:

- Temperature: YES if >38°C or <36°C, NO if 36-38°C, MISSING otherwise
- Heart rate: YES if >90 beats/minute, NO if ≤90 beats/minute, MISSING otherwise
- Respiration: YES if respiratory rate >20 breaths/min OR PaCO₂ <32 mm Hg or <4.3 kPa, NO if respiratory rate ≤20 breaths/min, MISSING otherwise
- White blood cell (WBC): YES if >12,000/mm³ or <4,000/mm³, NO if 4,000-12,000/mm³, MISSING otherwise

SIRS total = total of (temperature, heart rate, respiration, WBC), with YES=1, NO=0 **SIRS missing** = number of missing elements of (temperature, heart rate, respiration, WBC) ² For details of how to derive in-hospital and post-discharge asepsis scores see Appendix B.



5. STATISTICAL ANALYSES

5.1 Baseline data

Baseline (i.e. patient demography and past history) characteristics will be described by treatment group for patients in the analysis population. **Tables T4** to **T6** will be used as templates for this.

Continuous variables will be summarised using the mean and standard deviation (SD) (or median and inter quartile range (IQR) if the distribution is skewed), and categorical data will be summarised as a number and percentage. The summary statistic headings given in **Tables T4** to **T6** are those we expect to use based on a-priori knowledge of the clinical measurements gained from previous studies. However, if distributional assumptions are not valid, changes will be made.

Any imbalances in the characteristics of the patients at the start of the study will be described but statistical tests for baseline imbalance will not be carried out.

5.2 Primary and secondary outcome data

5.2.1 Adjustment in models

The intention is to adjust all models for both stratification factors (centre and type of surgery) as fixed effects. Occasionally values of these variables may differ between the study database and the randomisation system; in this case inconsistent values will be queried and ultimately values from the study database will be used.

For rare binary outcomes, where the data are insufficient to allow estimation of regression coefficients for these stratification variables, the analyses will be unadjusted.

Analyses of the neurocognitive outcomes will be adjusted for reading ability at recruitment (Wechsler Test of Adult Reading), medication (any medication given vs no medication), GHQ-30 (≥72 vs <72), HADS-Anxiety (≥8 vs <8) and HADS-Depression (≥8 vs <8) measured preoperatively, in addition to the stratification variables.

GHQ-30, HADs and medication data are also collected at 4-7 days and 3 months. The treatment effect will be estimated with and without the inclusion of these "updated" covariates in the model.

For continuous outcomes that are measured pre-operatively as well as post-operatively, preoperative and postoperative values will be modelled jointly in preference to the pre-operative value being modelled as a covariate. Joint modelling will avoid the necessity to either exclude cases with missing pre-operative measures or to impute missing pre-operative values.

5.2.2 Descriptive analyses

The distribution of neurocognitive outcomes, for those with and without reading difficulties and with and without mental health issues will be described.

5.2.3 Analysis models

All outcomes listed in the study protocol will be presented as per the template tables **Table T7** to **T14** and **Figure F2 to F6.** General methods of presentation and assessing treatment effects are outlined below. For all treatment comparisons the generic algorithm group will be the reference group. Details specific to each outcome are described as appropriate.

Date type	Outcomes
Binary	RBC blood transfusions
	Clinical outcomes (stroke, STEMI, acute kidney injury and
	respiratory complications)
Continuous	Cerebral oxygenation during operation (NIRS)
Time to event	Duration of ITU stay
	Duration of hospital stay
	All-cause mortality within 30 days of surgery
Longitudinal	Quality of life (EQ5D)



Cognitive functions (Primary outcome) Arterial oxygen delivery and utilisation during CPB Biomarkers of organ injury (S100/100B, troponin, creatinine clearance, Interleukins, urinary markers)

 Binary outcomes will be presented as numbers and percentages of patients in each treatment group. Outcomes will be compared between treatment groups using logistic regression. Treatment comparison estimates will be presented as adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Formal statistical comparisons of treatment effects will only be performed if more than ten patients in total experience the outcome (with at least one event in each treatment group).

For the presentation of transfusion outcomes see **Table T9** and **Figure F2**. Although the any transfusion vs. no transfusion will be compared, the number of units of RBC transfused will be described in each group (i.e. by the number of patients with 0, 1, 2, 3 and >3 transfusions).

- Continuous outcomes will be summarised by the mean and SD in each treatment group, if distributions are approximately normal. If distributions are non-normal, data may be summarised by the median and IQR or geometric mean (GM) if a logarithmic transformation provides an approximately normal distribution. Outcomes will be compared using linear regression. For untransformed data treatment, comparisons will be presented as adjusted differences in means with 95% CI, and for logarithmically transformed data as adjusted ratios of GMs with 95% CI.
- Time to event outcomes will be presented as medians and IQRs, estimated from survival modelling, and compared using adjusted Cox proportional hazards models. Therefore treatment comparisons will be presented as hazard ratios (HR) and 95% CI. The validity of the assumption of proportional hazards will be tested and, if this assumption is not met for treatment group, a Cox model with a time-dependent covariate (the interaction term between the treatment and the survival time) will be used. This type of model will allow the difference between the two groups to be estimated within discrete time periods. Models will be stratified by centre to allow for separate baseline hazard functions for each centre. If the proportional hazards assumption is not met, options such as stratification or fitting interaction terms will be explored. Patients who die will be censored at their time of death.

Outcome	Censor variable
Duration of post-randomisation ICU/HDU stay	Time of death in ICU/HDU
Duration of post-operative hospital stay	Time of death in hospital
All-cause mortality	Time of last follow-up (usually 3 months post- operation)

- **Continuous longitudinal outcomes** will be summarised as means and SDs (or medians and IQRs if distributions are skewed) at each time point. Outcomes will be compared using linear mixed effects methodology with the treatment group and study design variables (see **section 5.2.1**) fitted as fixed effects, and patient terms as random effects. Three approaches will be considered:
 - a) Fitting time as a categorical variable (i.e. ignoring information on the actual time the measurement was taken) and investigating different variance/covariance structures to best allow for the correlation between measurements taken at different times for the same patient. Variance/covariance structures will be compared using likelihood ratio tests. If a time x treatment interaction term is statistically significant at the 10% level then separate treatment effect estimates at each time point will be presented. If the interaction is not statistically significant an overall treatment effect will be reported.



- b) Fitting time as a continuous variable, with random intercepts (patient IDs) and slopes (time), to allow for different trajectories for different patients. This approach takes into account the actual times the measurements were taken. Quadratic time terms (e.g. time²) will be included if appropriate, i.e. dependent on model diagnostic plots.
- c) Fitting time as area under a curve. Adjusting for operation type will allow for individual patient profiles to be compared.

For outcomes assessed at specified time points (e.g. EQ5D) approach a) will be used. For NIRS c) will be used.

For both approaches b) and c) separate parameter estimates will be incorporated into models for: 1) the mean baseline response across both treatment groups and 2) at post-intervention time points for each treatment. This approach avoids the necessity to either exclude cases with missing baseline measures or to impute missing baseline values (see **section 5.2.1**). Treatment comparisons will be presented as adjusted differences in means with 95% CI, and for logarithmically transformed data as adjusted ratios of GMs with 95% CI.

Very low concentrations of biomarkers cannot be detected reliably from the assay (they are below the lower limit of detection, LLD). Therefore, any value less than the LLD will be treated as "<LLD" and not as a genuine reading. Methods of handling values below the LLD will be investigated and alternative methods will be used (e.g. replacing these with a value which is half the LLD, or estimating from a uniform distribution between a fixed lower value and the LLD or fitting a two part model for mixed discrete-continuous outcomes) depending on the number of values below the LLD.

Outcomes may also be presented graphically, if appropriate. For time to event outcomes this will usually consist of Kaplan-Meier survival curves. For continuous outcomes this may consist of graphs depicting estimated means (plus 95% CI or standard error) for each treatment group.

5.2.4 Statistical significance

For hypothesis tests two-tailed p-values<0.05 are considered statistically significant. The only exception to this is tests for interactions where a 10% threshold will be used as such tests have low power. Likelihood ratio tests will be used in preference to Wald tests for hypothesis testing.

The study assesses multiple neurocognitive functions as part of the primary outcome however no adjustment is intended to be made for multiple testing (see Section 5.2.8). When interpreting the primary outcome results against the study hypotheses, if either all six dimensions or four out of six statistically significant at the 5% level we would suggest this gives evidence to support the study hypotheses. Any other combinations will be considered insufficient evidence for the study hypotheses.

5.2.5 Model assumptions

For all methods outlined, underlying assumptions will be checked using standard methods, e.g. residual plots, tests for proportional hazards, etc. If assumptions are not valid then alternative methods of analysis will be sought. If outlying observations are found which mean models do not fit the data adequately, such observations will be excluded from the main analyses and comments made in footnotes. Sensitivity analyses will be performed to examine the effect on the study's conclusions of excluding outlying observations; any change in the study's conclusions would be reported.

5.2.6 Subgroup analyses

Some laboratory markers (S100, IL6, IL8, NGAL, IL18, LFABP and KIM1) were only measured on a consecutive subgroup of patients. These are the only subgroup analyses planned.

5.2.7 Sensitivity analyses

No sensitivity analyses (other than assessing the impact of outliers, see section 5.2.4) are planned.



5.2.8 Missing data

In all tables missing data will be indicated by footnotes. If the amount of missing data differs substantially between treatment groups potential reasons will be explored.

- Missing predictors:
 - All potential predictors are preoperative measurements of continuous longitudinal outcomes, and due to the joint modelling approach described previously the handling of missing values for such data is considered in the context of missing longitudinal data (see below).
- Missing outcomes measured at one time point:
 - If the proportion of missing data is less than 5% then complete case analysis will be performed (i.e. excluding cases with missing data).
 - If the proportion of missing data is between 5% and 15% conditional mean imputation methods will be used. This involves predicting the outcome from a regression model from (linearly related) covariate(s). These covariates will include the design variables, plus other potentially important covariates (e.g. age, gender, additive EuroSCORE).
 - If the proportion of missing data is above 15% multiple imputation methods will be considered. A general imputation model that uses an iterative procedure to generate imputed values will be used to generate multiple complete data sets (e.g. using Stata's mi impute). The model of interest will be the fitted to each of the complete data sets and effect estimates combined using Rubin's rules.
- Missing longitudinal data:
 - For continuous data measured at multiple time points preoperative values will be modelled jointly with those measured postoperatively, as described previously, thereby allowing all cases with at least one observation to be included. If appropriate (the level of missingness is >20%) then any variables that are predictive of missingness will be identified, and if there is reason to suggest that an assumption of missing at random (MAR) given these variables is reasonable (especially likely if the variable was measured pre-operatively) then such variables will be adjusted for in the models of interest. These models can be shown to provide unbiased estimates of the treatment effect and moreover multiple imputation approaches would not be expected to recover any additional information.

5.2.9 Multiple testing

No formal adjustment will be made for multiple testing (see Section 5.2.3 for discussion in relation to primary outcomes). However as previously described formal statistical comparisons will not be made for outcomes with low event rates and only pre-specified subgroup analyses will be performed. Consideration will be taken in interpretation of results to reflect the number of statistical tests performed and the consistency, magnitude and direction of treatment estimates for different outcomes.

5.3 Safety data

Adverse events occurring in the study period for all patients in the safety population will be tabulated as per **Table T15**.

Table T15 summarises expected adverse events listed in the study protocol, with events that meet the serious criteria² indicated. Such events are captured via the study CRFs. It also summarises

² An event is classified as serious if it meets one or more of the following criteria: a) resulted in death, b) was life threatening, c) resulted in persistent or significant disability/incapacity, d) prolonged an ongoing hospitalisation or resulted in hospitalisation



unexpected SAEs, i.e. events that are not listed in the study protocol that meet the serious criteria. Such events are captured via separate SAE report forms.

No formal comparisons between treatment groups will be made, as numbers of events are expected to be small.

6. **BIBLIOGRAPHY**

- Lezak M.D. Neuropsychological assessment, 3rd Edition. Oxford University Press (New York): 1995
- 2. Spreen O. and Strauss E. A compendium of neuropsychological tests. Oxford University Press (New York): 1998
- Mahanna, E. P., Blumenthal, J. A., White, W. D., Croughwell, N. D., Clancy, C. P., Smith, R., & Newman, M. F. Defining Neuropsychological Dysfunction After Coronary Artery Bypass Grafting. *Annals of Thoracic Surgery*. 1996; 61(5): 1342-1347
- 4. Weschler D. Manual of the Wechsler Adult intelligence scale revised. Psychological Corporation, Iglesias (New York): 1981
- 5. Benton A. and Hamsher R. Multilingual Aphasia Examination. University of Iowa (Iowa City): 1976
- 6. Wechsler D. Manual of the Wechsler Test of Adult Reading (WTAR-UK). New York Psychological Corporation (Iglesias): 2001
- 7. Zigmond, A. S. & Snaith, R. P. The Hospital Anxiety and Depression Scale. *Acta Psychiatrica Scandinavica*. 1983; 67(6): 361-370
- Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998;273: 4135– 41
- 9. Portilla D, Dent C, Sugaya T et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2007;73:465–472.
- 10. Gavin J. Murphy, F.R.C.S et al. Liberal or Restrictive Transfusion after Cardiac Surgery. N Engl J Med 2015; 372:997-1008March 12, 2015DOI: 10.1056/NEJMoa1403612
- 11. D. P. GOLDBERG, R. GATER, N. SARTORIUS, T. B. USTUN, M. PICCINELLI, O. GUREJE and C. RUTTER (1997). The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychological Medicine, 27, pp 191-197.
- Bjelland, I; et al. (2002). "The validity of the Hospital Anxiety and Depression Scale. An updated literature review". *Journal of Psychosomatic Research* 52 (2): 69–77. doi:10.1016/s0022-3999(01)00296-3 PMID 11832252.

7. AMENDMENTS TO THE SAP

Previous version	Previous date	New version	New date	Brief summary of changes



APPENDIX A: SKELETON TABLES AND FIGURES

Section	Outputs			
Section 1	Tables, figures and listings detailing the study population			
Population	Figure F1	Flow of participants		
	Table T1	Protocol deviations		
	Table T2	Details of protocol deviations		
	Table T3	Withdrawals		
Section 2	Summary table	s of demographic information		
Baseline data	Table T4	Patient demography and past history		
	Table T5	Intraoperative characteristics*		
Section 3	Summary data	and treatment estimates for primary and secondary outcomes		
Primary and	Table T6	Post-operative characteristics (not listed as outcomes)*		
secondary	Table T7	Primary outcome		
	Table T8	Medications at 3 months		
	Table T9	Secondary outcomes		
	Figure F2	Secondary outcome: Transfusions		
	Figure F3	Secondary outcome: Cerebral oxygenation during the operative period		
	Figure F4	Secondary outcome: Mean oxygen delivery during CPB		
	Table T10	Secondary outcomes: Biomarkers		
	Figure F5	Secondary outcome: Kaplan-Meier estimates of time to hospital discharge		
	Table T11	Secondary outcomes: categorical EQ5D outcomes		
	Table T12	Secondary outcomes: continuous EQ5D outcomes		
	Table T13	Secondary outcomes: categorical HADS and GHQ responses*		
	Table T14	Secondary outcomes: continuous HADS and GHQ responses categorised by thresholds		
Section 4	Summary table	les and listings of all adverse events and serious adverse events		
Safety data	Table T15	Adverse events and serious adverse events both in-hospital and during trial follow-up		

*These are likely to be put in an appendix in the final publication



Figure F1 Flow of participants Assessed for eligibility (n=XX) Patients excluded (n=XX) Ineligible (n=XX): Aged less than 16 (xx), Not valve/CABG and valve surgery (xx), emergency surgery (xx), belief system preventing transfusion (xx), elevated preoperative Hb requirement (xx), congenital or acquired RBC (xx), platelet or clotting factor disorders (xx), active inflammatory state or sepsis (xx), end stage renal failure (xx), or previous renal transplant (xx), neurological disorder (xd), diagnosed psychiatric disorder or drug/alcohol addiction (xx), previously indentified cognitive impairment (xx), previous stroke/ intra-creerbrain haemorrhage/ or acquired brain injury (xx), unable to complete neurocognitive assessments due to physical disability (xx), not able to give full informed consent (xx), in other clinical trial (xx). Not approached (n=XX): Did not consent (n=XX): Ineligible post consent n=XX): score<24 (xx) Other (n=XX) s, e.g. patient withdrawn post-consent but pre-randomisation Randomised (n=XX) Allocated to generic algorithm (n=XX) Allocated to patient-specific algorithm (n=XX) Withdrawals pre-surgery Withdrawals pre-surgery (n=XX): (n=XX): Reasons for withdrawal Reasons for withdrawal **Deaths pre-surgery Deaths pre-surgery** (n=XX) (n=XX) Underwent surgery and included in Underwent surgery and included in analysis population (n=XX) analysis population (n=XX) Number of protocol deviations Number of protocol deviations Withdrawals post-Withdrawals postsurgery (n=XX): surgery (n=XX): Reasons for withdrawal Reasons for withdrawal **Deaths post-surgery Deaths post-surgery** (n=XX) (n=XX) 3 month follow-up data available (n=XX) 3 month follow-up data available (n=XX)

Notes:

¹ Some patients may be ineligible for more than one reason



Table T1Protocol deviations

	Randomised to Generic algorithm (n=XX)		Randomised to patient-specific algorithm (n=XX)		Overall (n=XX)	
	Patients	%	Patients	%	Patients	%
ANY PROTOCOL DEVIATION						
Allocated treatment adherence						
Ineligible but treated						
Did not receive any intervention						
Transfusion threshold adherence						
Transfused above HCT 23 (conventional group)						
Transfused above HCT 18 without Murkin protocol being followed (patient-specific group)						
Did not receive a transfusion when HCT dropped below 23 (conventional group)						
Did not receive a transfusion when HCT dropped below 18						
Other non-adherence						
Murkin protocol not followed when NIRS reading drops below 70% of baseline or absolute value of 50%						
Murkin algorithm followed for patient in conventional group i.e patient crossed-over between treatment groups						

Table T2Details of protocol deviations

Allocated treatment		
group	Centre	Further details (exact nature dependent upon type of deviation)



Table T3Withdrawals

		Rando Ge algo (n:	Randomised to Generic algorithm (n=XX)		Randomised to patient-specific algorithm (n=XX)		rall (x)
_		n	%	n	%	n	%
Any withdrawal							
Of those who withdre	ew:						
Time of withdrawal	Pre-op						
	Intra-op						
	Post-op						
Decision taken by	Patient						
	Clinician						
Reason for	Reason 1						
withdrawal	Reason 2						
	Reason 3						
	etc						

Patient demography and past history

Randomised to Randomised to Generic patient-specific algorithm algorithm Overall (n=XX) (n=XX) (n=XX) n % n % n % **BASELINE CHARACTERISTICS** Height Mean(SD) Weight Mean(SD) NHYA class I Ш |||IV CSS class Asymptomatic I Ш III IV **ANGIOGRAM/ ECHO RESULTS** LV function Good (>50%) Moderate (30-50%) Poor<30%) >50% disease in left main stem

Table T4



		Randomised to Generic algorithm (n=XX)		Randomised to patient-specific algorithm (n=XX)		Overall (n=XX)	
		n	%	n	%	n	%
Coronary disease,	e						
number of vessels	Single						
	Double						
	Triple						
	None						
	Not						
	Investigated						
Haemoglobin	Median (IQR)						
Haematocrit	Median (IQR)						
Platelets	Median (IQR)						
Creatinine value	Median (IQR)						
Urine output over 3	Madian (IOD)						
	wedian (IQR)						
	la sulla						
Diabetes	Insulin						
	Oral						
	Diet						
Descentes	NO						
Pacemaker	Permanent						
	lemporary						
	No						
Heart rhythm	Sinus						
	Block						
	Paced						
CVA/TIAs							
Smoking status	Smoker						
	Ex-smoker						
	Non-smoker						
EuroSCORE							
Operative priority	Elective						
	Urgent						
MEDICATIONS							
Pre-operative medicat	ions						
Heparin							
Nitrates until theatre							
Clexane within 12							
hours pre-op							
Inotropes until theatre							



	Randor Ger algo (n=	Randomised to Generic algorithm (n=XX)		Randomised to patient-specific algorithm (n=XX)		erall XX)
	n	%	n	%	n	%
Aspirin within 5 days pre-op						
Clopidogrel within 5 days pre-op						
Psychotic medications						
Hypnotics						
Sedatives						
Neuroleptics						
Anxiolytics						
Antidepressants						
Beta blockers						
Any psychotic drug						
The Wechsler Test of Adult Reading	ng					
WTAR standard score Median (IC	QR)					

Table T5 Intraoperative characteristics

		Randomised to Generic algorithm (n=XX)		Randomised to patient-specific algorithm (n=XX)		Ove (n=	erall XX)
		n	%	n	%	n	%
BYPASS DATA							
Duration of operation (hours)	Median (IQR)						
Bypass duration (mins)	Median (IQR)						
Cross clamp duration (mins)	Median (IQR)						
Type of surgery	Valve						
	CABG and Valve						
Myocardial protection	Crystalloid						
	Blood						
	Other						
Type of circuit	Closed						
	Open						
Coated circuit							
Oxygenator	D903						
	EOS						



		Randomised to Generic algorithm (n=XX)		Randomised to patient-specific algorithm (n=XX)		Ove (n=	erall XX)
		n	%	n	%	n	%
	Quadrox						
Prime volumes in bypass circuit:							
Crystolloid	Median (IQR)						
Colloid	Median (IQR)						
Mannitol	Median (IQR)						
Blood	Median (IQR)						
VALVES							
Aortic	Repaired						
	Replaced						
Mitral	Repaired						
	Replaced						
Tricuspid	Repaired						
	Replaced						
Pulmonary	Repaired						
	Replaced						

Table T6	Post-operative characteristics (Appendix table)
	rost-operative characteristics (Appendix table)

		Randomised to Generic algorithm (n=XX)		Random patient-s algorithn	nised to specific n (n=XX)	Overall (n=XX)	
		n	%	n	%	n	%
ON RETURN FROM	I THEATRE						
Temperature	Median (IQR)						
Hct	Median (IQR)						
Lactate	Median (IQR)						
MABP	Median (IQR)						
PaO ₂	Median (IQR)						
PaCo ₂	Median (IQR)						
BLOOD RESULTS	(1 st 24 HOURS)						
Lowest Hb	Median (IQR)						
Lowest Hct	Median (IQR)						
Lowest MABP	Median (IQR)						
Highest lactate	Median (IQR)						
BLOOD LOSS/ FLU	JID BALANCE						
Fluid balance at 12							
hours							

STATISTICAL ANALYSIS PLAN PASPORT



		Randomised to Generic algorithm (n=XX)		Randon patient- algorithr	nised to specific n (n=XX)	Ove (n=	erall XX)
		n	%	n	%	n	%
Total chest tube drainage at 4 hours	Median (IQR)						
Total chest tube drainage at 12							
hours	Median (IQR)						
RE-OPERATIONS							
Number of re-							
operations	Median (IQR)						
Type of reoperation	Chest re- opened						
	Other						
If chest re-opened	Tamponade						
	Bleeding						
	Mediastinitis						
	Cardiac arrest						
	Low cardiac						
	output						
	Other						
Re-intubated							



Table T7Primary outcome

		Randomised to Generic algorithm (n=XX)		Randomised to patient-specific algorithm (n=XX)		Effect ¹	
		Mean	SD	Mean	SD	(95% CI)	p-value
COGNITIVE FUN	CTION						
1. Attention - TRAI	L MAKING						
Trail B	Baseline						
completion (seconds)	5 days post- op					MD/GMR	
	3 months post-op					MD/GMR	
	Treatment *time interaction						
	Overall					MD/GMR	
2. Verbal memory -	RAVLT						
Trial VI having	Baseline						
adjusted for age	5 days post- op					MD/GMR	
	3 months post-op					MD/GMR	
	Treatment *time interaction						
	Overall					MD/GMR	
3. Visuo-spatial ski	ills - WAIS III (We	chsler)					
Block design	Baseline						
having adjusted for age	5 days post- op					MD/GMR	
	3 months post-op					MD/GMR	
	Treatment *time interaction						
	Overall					MD/GMR	
4. Psychomotor sp	eed - WAIS III (W	echsler)					
b. Digital	Baseline						
symbol coding having adjusted	5 days post- op					MD/GMR	
for age	3 months post-op					MD/GMR	
	Treatment *time						
5. Verbal fluency -		APHASIA (C	ΟΨΔΤ)				
. Verbai indency -	Baseline						



Word score having adjusted for age and	5 days post- op		MD/GMR	
years of education	post-op Treatment *time interaction		MD/GMR	
	Overall		MD/GMR	
6. Visual motor coo	ordination - PEG	BOARD		
Peg board	Baseline			
completion (seconds)	5 days post- op		MD/GMR	
	3 months post-op		MD/GMR	
	Treatment *time interaction			
	Overall		MD/GMR	

Notes:

¹ OR=odds ratio, MD=Mean difference, GMR

Mean differences or geometric mean ratios for the cognitive functions may be presented for each time point or overall depending if there is a time by treatment interaction.

Data summarised will be scaled scores NOT raw scores.

All treatment estimates will be reported with and without adjustment for medications, HADs and GHQ measured after surgery.

Table T8Medications at 3 months

	Randomised to Generic algorithm (n=XX)		Randomised to patient-specific algorithm (n=XX)		Overall (n=XX)	
	n	%	n	%	n	%
Psychotic medications						
Hypnotics						
Sedatives						
Neuroleptics						
Anxiolytics						
Antidepressants						
Beta blockers						
Any psychotic drug						



Table T9 Secondary outcomes

			Rai to al	ndomised Generic gorithm (n=XX)	Ra pa	andomised to tient-specific algorithm (n=XX)	Effect ¹ (95% CI)	p-value
			n	%	n	%		
1	The total number of RBCs units transfused	0						
		1						
		2						
		3						
		>3						
1	Any RBC units						RR	
1	Any FFP							
	Any platelets							
1	Any cryoprecipitates							
1	Any activated factor VII							
2	Cerebral oxygenatic	on during the						
	Minimum cerebral							
	oxygenation (%)							
	Area under the							
	curve	0						
3	Oxygen delivery during CPB	Start of CPB						
		20 minutes after the start of CPB						
		40 minutes after the start of CPB						
		Pre-warm						
		Pre-wean						
		Treatment *time interaction						
		Overall					MD/GMR	
	Oxygen utilisation during CPB	Start of CPB						
		20 minutes after the start of CPB						
		40 minutes after the start of CPB						
		Pre-warm						
		Pre-wean						



			Ra to a	ndomised Generic Igorithm (n=XX)	Ra pa	indomised to tient-specific algorithm (n=XX)	Effect ¹ (95% CI)	p-value
			n	%	n	%		
		Treatment *time interaction						
		Overall					MD/GMR	
5	Length of ICU/ HDU stay						HR	
6	Length of hospital stay						HR	
7	Any clinical outcome listed below						RR	
7		Infection						
7		Stroke						
7		STEMI						
7		Post-op kidney injury						
		Stage 1						
		Stage 2						
		Stage 3						
7		Respiratory complications						
9	Death within 30 days of surgery						HR	

Notes:

¹ RR=relative risk, MD=Mean difference, GMR=geometric mean ratio, HR=hazard ratio.



Figure F2 Secondary outcome: Transfusions



Notes:

It may be necessary to give treatment effect estimates either for each time point or overall, depending on if a treatment*time interaction term is found to be required in the model.



		Randomised to Generic algorithm (n=XX)	Randomised to patient- specific algorithm (n=XX)	Effect ¹ (95% CI)	p-value
BLOOD		× ,	. ,	× /	<u> </u>
S100/100B (brain)	Pre-op			MD/ GMR	
	Return from ITU				
	6 hrs post-op				
	24 hrs post-op				
	48 hrs post-op				
	96 hrs post-op				
Time* treatment interaction					
Overall treatment effect					
Troponin T (heart)	Pre-op			MD/ GMR	
	Return from ITU				
	6 hrs post-op				
	24 hrs post-op				
	48 hrs post-op				
	96 hrs post-op				
Time* treatment interaction					
Overall treatment effect					
Creatinine clearance (kidney)	Pre-op			MD/ GMR	
	Return from ITU				
	6 hrs post-op				
	24 hrs post-op				
	48 hrs post-op				
	96 hrs post-op				
Time* treatment interaction					
Overall treatment effect					
IL6	Pre-op			MD/ GMR	
	Return from ITU				

Table T10 Secondary outcomes: Biomarkers



			Randomised to Generic algorithm (n=XX)	Randomised to patient- specific algorithm (n=XX)	Effect ¹ (95% CI)	p-value
		6 hrs post-op				-
		24 hrs post-op				
		48 hrs post-op				
		96 hrs post-op				
	Time* treatment interaction					
	Overall treatment effect					
	IL8	Pre-op			MD/ GMR	
		Return from ITU				
		6 hrs post-op				
		24 hrs post-op				
		48 hrs post-op				
		96 hrs post-op				
	Time* treatment interaction					
	Overall treatment effect					
URINE						
	Urinary creatinine	Pre-op			MD/ GMR	
		6 hrs post-op				
		12 hrs post-op				
	Time* treatment interaction	24-48 nrs post-op				
	Overall treatment effect					
	NGAL	Pre-op			MD/ GMR	
		6 hrs post-op				
		12 hrs post-op				
		24-48 hrs post-op				
	Time* treatment interaction					
	Overall treatment effect					
	IL18	Pre-op			MD/ GMR	
		6 hrs post-op				



		Randomised to Generic algorithm (n=XX)	Randomised to patient- specific algorithm (n=XX)	Effect ¹ (95% CI)	p-value
	12 hrs post-op				
Time* treatment interaction	24-48 hrs post-op				
Overall treatment effect					
LFABP	Pre-op			MD/ GMR	
	6 hrs post-op 12 hrs post-op 24-48 hrs post-op				
Time* treatment interaction					
Overall treatment effect					
KIM1	Pre-op			MD/ GMR	
	6 hrs post-op				
	12 hrs post-op				
Time* treatment interaction	24-48 hrs post-op				
Overall treatment effect					



Figure F3 Secondary outcome: Cerebral oxygenation during the operative period



Figure F4 Secondary outcome: Mean oxygen delivery and utilisation during CPB



Notes:

Many blood gas and blood test results are reported on the CRFs. All will be described graphically (example given below), with average results (either means and SDs, or medians and IQRs) at each time point, by group.



Figure F5 Secondary outcome: Kaplan-Meier estimates of time to hospital discharge



Notes:

The Kaplan-Meier curve will be repeated for time to CICU/HDU and death within 30 days of surgery.

Table T8 Secondary outcomes: categorical EQ5D outcomes

		Rando to Ge algo (n=	omised eneric rithm :XX)	Randor patient- algo (n=	nised to specific rithm XX)
Mobility		n	%	n	%
Pre-operative	I have no problems walking about				
	I have some problems walking about				
	I am confined to bed				
6 weeks post-	I have no problems walking about				
operative	I have some problems walking about				
	I am confined to bed				
3 months post-	I have no problems walking about				
operative	I have some problems walking about				
	I am confined to bed				
Self-care					
Pre-operative	I have no problems with self-care				
	I have some problems with self-care				
	I am unable to wash or dress myself				
6 weeks post-	I have no problems with self-care				
operative	I have some problems with self-care				
	I am unable to wash or dress myself				
	I have no problems with self-care				



3 months post-	I have some problems with self-care
operative	I am unable to wash or dress myself
Usual activities	
Pre-operative	I have no problems with doing my usual activities
	I have some problems with doing my usual activities
	I am unable to perform my usual activities
6 weeks post- operative	I have no problems with doing my usual activities
	I have some problems with doing my usual activities
	I am unable to perform my usual activities
3 months post- operative	I have no problems with doing my usual activities
	I have some problems with doing my usual activities
	I am unable to perform my usual activities
Pain/Discomfort	
Pre-operative	I have no pain or discomfort
	I have moderate pain or discomfort
	I have extreme pain or discomfort
6 weeks post-	I have no pain or discomfort
operative	I have moderate pain or discomfort
	I have extreme pain or discomfort
3 months post-	I have no pain or discomfort
operative	I have moderate pain or discomfort
	I have extreme pain or discomfort
Anxiety/Depressi	ion
Pre-operative	I am not anxious or depressed
	I am moderately anxious or depressed
	I am extremely anxious or depressed
6 weeks post-	I am not anxious or depressed
operative	I am moderately anxious or depressed
	I am extremely anxious or depressed
3 months post-	I am not anxious or depressed
operative	I am moderately anxious or depressed
	I am extremely anxious or depressed



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)	Effect (95% CI)	p-value
SINGLE SUMMARY IND	EX				
Pre-operative	Median (IQR)				
6 weeks post-operative	Median (IQR)				
3 months post-operative	Median (IQR)				
Test for treatment*time int	teraction				
Overall estimate of treatm	ent effect				
VISUAL ANALOGUE SC	ALE				
Pre-operative	Mean (SD)				
6 weeks post-operative	Mean (SD)				
3 months post-operative	Mean (SD)				
Test for treatment*time interaction					
Overall estimate of treatm	ent effect				

Table T12 Secondary outcomes: continuous EQ5D outcomes

Notes:

It may be necessary to give treatment effect estimates either for each time point or overall, depending on if a treatment*time interaction term is found to be required in the model.

		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
I feel tense or w	ound up:		
Pre-operative	Most of the time		
	A lot of the time		
	Time to time		
	Not at all		
5 days post-	Most of the time		
operative	A lot of the time		
	Time to time		
	Not at all		
3 months post-	Most of the time		
operative	A lot of the time		
	Time to time		
	Not at all		
I still enjoy the t	hings I used to enjoy:		
Pre-operative	Definitely as much		
	Not quite so much		
	Only a little		
	Hardly at all		
	Definitely as much		

Table T13 Mental health: categorical HADS and GHQ responses



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
5 days post-	Not quite so much		,
operative	Only a little		
	Hardly at all		
3 months post-	Definitely as much		
operative	Not quite so much		
	Only a little		
	Hardly at all		
I get a sort of frig	ghtened feeling as if		
sometning awrui	Is about to nappen:		
Pre-operative	badly		
	Yes, but not too badly		
	A little, but it doesn't worry me		
	Not at all		
5 days post- operative	Very definitely and quite badly		
	Yes, but not too badly		
	A little, but it doesn't worry		
	Not at all		
3 months post-	Very definitely and quite		
oporativo	Yes, but not too badly		
	A little, but it doesn't worry		
	me		
	Not at all		
I can laugh and s	see the funny side of things:		
Pre-operative	As much as I always could		
	Not quite as much now		
	Definitely not so much now		
	Not at all		
5 days post-	As much as I always could		
operative	Not quite as much now		
	Definitely not so much now		
	Not at all		
3 months post-	As much as I always could		
operative	Not quite as much now		
	Definitely not so much now		
	Not at all		
Worrying though	nts go through my mind:		
Pre-operative	A great deal of the time		
	A lot of the time		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
	From time to time but not too often		
	Only occasionally		
5 days post-	A great deal of the time		
operative	A lot of the time		
	From time to time but not too often		
	Only occasionally		
3 months post-	A great deal of the time		
operative	A lot of the time		
	From time to time but not too often		
	Only occasionally		
I feel cheerful:			
Pre-operative	Not at all		
	Not often		
	Sometimes		
	Most of the time		
5 days post-	Not at all		
operative	Not often		
	Sometimes		
	Most of the time		
3 months post-	Not at all		
operative	Not often		
	Sometimes		
	Most of the time		
I can sit at ease	and feel relaxed:		
Pre-operative	Definitely		
	Usually		
	Not often		
	Not at all		
5 days post-	Definitely		
operative	Usually		
	Not often		
	Not at all		
3 months post-	Definitely		
operative	Usually		
	Not often		
	Not at all		
I feel as if I am s	lowed down:		
Pre-operative	Nearly all the time		
	_ Very often		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
	Sometimes		
	Not at all		
5 days post-	Nearly all the time		
operative	Very often		
	Sometimes		
	Not at all		
3 months post-	Nearly all the time		
operative	Very often		
	Sometimes		
	Not at all		
I get a sort of frig butterflies in the	ghtened feeling like stomach:		
Pre-operative	Not at all		
	Occasionally		
	Quite often		
	Very often		
5 days post-	Not at all		
operative	Occasionally		
	Quite often		
	Very often		
3 months post-	Not at all		
operative	Occasionally		
	Quite often		
	Very often		
I have lost intere	st in my appearance:		
Pre-operative	Definitely		
	l don't take as much care as l should		
	l may not take quite as much care		
	l take just as much care as ever		
5 days post-	Definitely		
operative	l don't take as much care as l should		
	l may not take quite as much care		
	I take just as much care as ever		
3 months post-	Definitely		
operative	I don't take as much care as I should		
	I may not take quite as much care		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
	I take just as much care as ever		
I feel restless as	if I have to be on the move:		
Pre-operative	Very much indeed		
	Quite a lot		
	Not very much		
	Not at all		
5 days post-	Very much indeed		
operative	Quite a lot		
	Not very much		
	Not at all		
3 months post-	Very much indeed		
operative	Quite a lot		
	Not very much		
	Not at all		
I look forward wi	th enjoyment to things:		
Pre-operative	As much as I ever did		
	Rather less than I used to		
	Definitely less than I used to		
	Hardly at all		
5 days post-	As much as I ever did		
operative	Rather less than I used to		
	Definitely less than I used to		
	Hardly at all		
3 months post-	As much as I ever did		
operative	Rather less than I used to		
	Definitely less than I used to		
	Hardly at all		
I get sudden feel	ings of panic:		
Pre-operative	Very often indeed		
	Quite often		
	Not very often		
	Not at all		
5 days post-	Very often indeed		
operative	Quite often		
	Not very often		
	Not at all		
3 months post-	Very often indeed		
operative	Quite often		
	Not very often		
	Not at all		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
I can enjoy a goo programme:	od book or radio or TV		
Pre-operative	Often		
·	Sometimes		
	Not often		
	Very seldom		
5 days post-	Often		
operative	Sometimes		
	Not often		
	Very seldom		
3 months post-	Often		
operative	Sometimes		
	Not often		
	Very seldom		
GHQ-30			
1 – been able to you're doing?	concentrate on whatever		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
2 – lost much slo	eep over worry?		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
3 – been having	restless, disturbed nights?		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
4 – been managi occupied?	ng to keep yourself busy and		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
5 – been getting usual?	out of the house as much as		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
6 – been managi would in vour sh	ng as well as most people loes?	, , , , , , , , , , , , , , , , , , ,	<u> </u>
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
7 – felt on the wh well?	nole you were doing things		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
8 – been satisfie out your task?	d with the way you've carried		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
9 – been able to	feel warmth and affection for		<u> </u>
those near you?			
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
10 – been finding people?	g it easy to get on with other		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
11- spent much t	ime chatting with people?		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
12 – felt that you things?	are playing a useful part in	· · ·	
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
13 – felt capable things?	of making decisions about		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
14 – felt constan	tly under strain?		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
15 – felt you cou difficulties?	ldn't overcome your		
Pre-operative	Better than usual		
-	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
16 – been finding	g life a struggle all the time?		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
17 – been able to day activities?	o enjoy your normal day-to-		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
J uays post-	Samo as usual		
operative	Same as usual		
operative	Less than usual		
operative	Less than usual Much less than usual		
operative 3 months post-	Less than usual Much less than usual Better than usual		
3 months post- operative	Less than usual Much less than usual Better than usual Same as usual		
operative 3 months post- operative	Less than usual Much less than usual Better than usual Same as usual Less than usual		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
19 – been getting good reason?	g scared or panicky for no		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
20 – been able to	o face up to your problems?		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
21 – found every	thing getting on top of you?		
Pre-operative	Better than usual		
	Same as usual		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
22- been feeling	unhappy or depressed?		
Pre-operative	Better than usual		
-	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
23 – been losing	g confidence in yourself?		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
24 – been thinki person?	ng of yourself as a worthless		
Pre-operative	Better than usual		
·	Same as usual		
	Less than usual		
	Much less than usual		
person? Pre-operative	Better than usual Same as usual Less than usual Much less than usual		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
25 – felt that life i	is entirely hopeless?		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
26 – been feeling future?	hopeful about your own		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
27 – been feeling things considere	reasonably happy, all d?		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
	Better than usual		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
5 days post-	Same as usual		
operative	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
28 – been feeling	g nervous and stung-up all		
the time?			
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
29 – felt that life	isn't worth living?		
Pre-operative	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
3 months post-	Better than usual		
operative	Same as usual		
	Less than usual		
	Much less than usual		
30 – found at tim because your ne	es you couldn't do anything erves were too bad		
Pre-operative	Better than usual		
r	Same as usual		
	Less than usual		
	Much less than usual		
5 days post-	Better than usual		
operative	Same as usual		
	_		



		Randomised to Generic algorithm (n=XX)	Randomised to patient-specific algorithm (n=XX)
3 months post- operative	Less than usual		
	Much less than usual		
	Better than usual		
	Same as usual		
	Less than usual		
	Much less than usual		

Table T14 Mental health: continuous HADS and GHQ responses

	Randomised to Generic algorithm		Randomised to patient- specific algorithm	
	(n=)	XX)	(n=X)	K)
	median	IQR	median	IQR
ANXIETY SUMMARY MEASURE				
Pre-operative				
5 days post-operative				
3 months post-operative				
DEPRESSION SUMMARY MEASURE				
Pre-operative				
5 days post-operative				
3 months post-operative				
GHQ30 SUMMARY MEASURE				
Pre-operative				
5 days post-operative				
3 months post-operative				

Notes

Numbers above and below thresholds will be included as footnotes. HADS-Anxiety (≥8 vs <8), HADS-Depression (≥8 vs <8) and GHQ-30 (≥72 vs <72).



Table T15Adverse events and serious adverse events in-hospital and during trialfollow-up (excluding secondary outcomes) follow-up

	Randomised to Generic algorithm (n=XX)			Randomised to patient- specific algorithm (n=XX)								
							Patients					
	Eve	ents	Patie	ents	s (n=X	X) ∞	Ev	ents	۸E	(n= ∞	XX)	0/
EXPECTED EVENTS		JAL	AL	70	JAL	/0	AL	JAL	AL	70	JAL	70
Cardiac arrest												
SVT/ VF												
VF/ VT												
New pacing												
Single												
Double												
Permanent												
Any inotropes												
IABP inserted												
Pulmonary artery catheter												
Vasodilator used												
Low cardiac output												
Tracheostomy												
Mask CPAP												
ARDS												
Pneumothorax or effusion requiring draining												
Haemofiltration/ dialysis since heart operation												
Gut infarction												
Peptic ulcer/ GI bleed/ perforation												
Pancreatitis												
Other GI												
TIA												
DVT												
Pulmonary embolism												
Excessive bleeding not requiring re-operation												
Wound dehiscence												
UNEXPECTED EVENT												
Details												



APPENDIX B: ASEPSIS SCORES

In-hospital asepsis scores

For each wound used in the operation (a minimum of one – chest – and a maximum of six – chest, left leg, right leg, left arm, right arm, other, per patient) a wound specific in-hospital asepsis score is derived using the following steps:

- 1. A daily score is derived for each of the days that the wound was scored (ideally scored on three separate occasions), from the following:
 - If both filter questions (wound hot/wound wet) are "No" then the daily score is zero.
 - Otherwise the daily score is derived from summing the points awarded as follows for the four proportions of wound affects answers given on the CRF:

Proportion of wound affected:	0%	<20%	20-39%	40-59%	60-79%	>80%
Serous exudates	0	1	2	3	4	5
Erythema	0	1	2	3	4	5
Purulent exudates	0	2	4	6	8	10
Wound separation	0	2	4	6	8	10

Note: Any missing scores will be assumed to be 0, unless all four scores are missing and then the daily score will be set to be missing.

- 2. Data collection is ideally performed on days 3, 5 and 8 post-operatively. The following rules are used to determine if daily scores are valid:
 - A two day window is allowed either side of the intended day, so for example the day 3 score can be done between day 1 and day 5³.
 - Any assessments done outside of these windows, after the date of discharge, or in an invalid order (e.g. day 5 done before day 3) are invalid and not used.
 - A minimum of one daily score is required to proceed further. If this is not the case then the inhospital asepsis score for that wound is missing.
- 3. Scores for days 1 to 10 are calculated; scores for missing days are either propagated from the nearest score or interpolated between scores. Note that the actual day of assessment is used rather than the intended day. See the following examples:

	EXAMPLE 1		EXAMPLE 2	
Day (post-op)	Score	Rule	Score	Rule
1	3	Propagate	6	Propagate
2	3	Observed	6	Propagate
3	2.25	Interpolate	6	Observed
4	1.5	Interpolate	8	Interpolate
5	0.75	Interpolate	10	Observed
6	0	Observed	8	Interpolate
7	0	Propagate	6	Interpolate
8	0	Propagate	4	Interpolate
9	0	Propagate	2	Interpolate
10	0	Propagate	0	Observed

4. Any daily scores after day 7 are then discarded. The remaining scores are summed and then multiplied by 5/7 to give a single score representing five days' worth of daily asepsis scores.

³ Note the day 8 score is intended to be performed on day 8 or, if the patient discharged sooner, on the day of discharge. Therefore if the patient is discharged prior to day 8 the allowed window will be within two days of discharge (for example if the patient is discharged on day 6 the window will be day 4 to day 6)

STATISTICAL ANALYSIS PLAN PASPORT



- 5. The final in-hospital asepsis score for the wound is then calculated from adding points to the score derived from point 4 if any of the following events occurred at any time in the post-operative stay for that wound:
 - Antibiotics given for wound infection: 10 points
 - Isolation of bacteria: 10 points
 - Drainage of pus under local anaesthetic: 5 points
 - Drainage of pus under general anaesthetic: 10 points
 - Length of hospital day >14 days: 5 points

Note: any missing elements will be assumed to be 0.

Post-discharge asepsis scores

Post-discharge asepsis scores are calculated by taking the in-hospital asepsis score for each wound and adding additional points if the patient has answered the questions on the 3-month follow-up questionnaire for that wound as follows:

- Been given antibiotics for wound infection=Yes AND patient did not have antibiotics for wound infection in initial hospital admission: 10 points
- Doctor opened/drained an abscess=Yes AND patient did not have drainage of pus under local anaesthetic in initial hospital admission: 5 points
- Wound been opened and cleaned under general anaesthetic in hospital=Yes AND patient did not have drainage of pus under general anaesthetic in initial hospital admission: 10 points
- Wound discharged pus=Yes AND the purulent exudates question on the in-hospital questionnaire was no/missing at all-time points: 5 points
- District nurse had to dress wound=Yes AND patient did not have drainage of pus under local anaesthetic in initial hospital admission: 5 points

Note: any missing elements will be assumed to be 0

